checkAd
    Startseite > Aktien > Antibe Therapeutics > Nachrichten
    Antibe Therapeutics Aktie
    0,0900
     
    CAD
    +1.700,00 %
    +0,0850 CAD
    Letzter Kurs 24.05.24 Toronto
    0,0900
     
    CAD
    12.000 STK
    Geldkurs 24.05.24
    0,0900
     
    CAD
    18.500 STK
    Briefkurs 24.05.24
    ISIN: CA0370255097 · WKN: A2QJPN · SYM: ATE · Kanada

    Neueste Nachrichten

    Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
    10.04.24 · Business Wire (engl.) · Antibe Therapeutics Registered (Old)
    Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
    09.04.24 · Business Wire (engl.) · Antibe Therapeutics Registered (Old)
    Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
    01.04.24 · Business Wire (engl.) · Antibe Therapeutics Registered (Old)
    Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
    20.03.24 · Business Wire (engl.) · Antibe Therapeutics Registered (Old)
    Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
    07.03.24 · Business Wire (engl.) · Antibe Therapeutics Registered (Old)
    Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
    04.03.24 · Business Wire (engl.) · Antibe Therapeutics Registered (Old)
    Antibe Reports Q3 2024 Interim Financial and Operating Results
    14.02.24 · Business Wire (engl.) · Antibe Therapeutics Registered (Old)
    Antibe Extends Early Warrant Exercise Incentive Program
    01.02.24 · Business Wire (engl.) · Antibe Therapeutics Registered (Old)
    Antibe Announces Early Warrant Exercise Incentive Program
    29.12.23 · Business Wire (engl.) · Antibe Therapeutics Registered (Old)
    Antibe Therapeutics Announces Amendment to Warrant Terms
    12.12.23 · Business Wire (engl.) · Antibe Therapeutics Registered (Old)
    Antibe Reports Q2 2024 Interim Financial and Operating Results
    13.11.23 · Business Wire (engl.) · Antibe Therapeutics Registered (Old)
    Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation
    09.11.23 · Business Wire (engl.) · Antibe Therapeutics Registered (Old)